Small-molecule inhibitors of protein–protein interactions: progressing towards the dream
The DOI matches its Crossref record; 180 of the 180 references it cites were found in a registry or an index.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, most of the activities of transcription factors are mediated by protein-protein interaction or binding to DNA in a sequence-specific fashion, both of which are conventionally considered challenging targets for development of small-molecule inhibitors (2).”
From Echinomycin, a small-molecule inhibitor of hypoxia-inducible factor-1 DNA-binding activity. (2005) · cites this paper as [2]
In the citing paper
“Undruggable proteins, which possess flat active sites, often act through PPI networks, which are characterized by large, flat, and undefined interfaces between proteins. These networks have been considered undruggable biological processes for decades.309–311”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [310]
Citations
Cites
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661
Nitric oxide synthases: structure, function and inhibition
ALDERTON, W. K., COOPER, C. E., & KNOWLES, R. G. (2001) · Biochemical Journal · doi:10.1042/bj3570593 · Cited by 4,110
The Bcl2 family: regulators of the cellular life-or-death switch
Cory, S., & Adams, J. M. (2002) · Nature Reviews Cancer · doi:10.1038/nrc883 · Cited by 4,032
BCL-2 family members and the mitochondria in apoptosis
Gross, A., McDonnell, J. M., & Korsmeyer, S. J. (1999) · Genes & Development · doi:10.1101/gad.13.15.1899 · Cited by 3,641
Nitric oxide and the immune response
Bogdan, C. (2001) · Nature Immunology · doi:10.1038/ni1001-907 · Cited by 3,447
Ghrelin: Structure and Function
Kojima, M., & Kangawa, K. (2005) · Physiological Reviews · doi:10.1152/physrev.00012.2004 · Cited by 2,810
CTLA-4 can function as a negative regulator of T cell activation
Walunas, T. L., Lenschow, D. J., Bakker, C. Y., Linsley, P. S., Freeman, G. J., Green, J. M., Thompson, C. B., & Bluestone, J. A. (1994) · Immunity · doi:10.1016/1074-7613(94)90071-x · Cited by 2,222
The mechanism of action of cyclosporin A and FK506
Schreiber, S. L., & Crabtree, G. R. (1992) · Immunology Today · doi:10.1016/0167-5699(92)90111-j · Cited by 2,127
Discovering High-Affinity Ligands for Proteins: SAR by NMR
Shuker, S. B., Hajduk, P. J., Meadows, R. P., & Fesik, S. W. (1996) · Science · doi:10.1126/science.274.5292.1531 · Cited by 2,041
Anatomy of hot spots in protein interfaces
Bogan, A. A., & Thorn, K. S. (1998) · Journal of Molecular Biology · doi:10.1006/jmbi.1998.1843 · Cited by 1,988
Research works printed but not linked: 4
- Das, R. C. & Morrow, K. J. J. in Antibody Engineering Report (Drug and Market Development Publications, 2002).
- Gibson, C. et al. Nonpeptidic α(v)β(3) Integrin antagonist libraries: on-bead screening and mass spectrometric identification without tagging. Angew. Chem. Int. Ed. Engl. 40, 165–169 (2001). · doi:10.1002/1521-3773(20010105)40:1<165::aid-anie165>3.0.co;2-8
- Raimundo, B. C. et al. Discovery of small-molecule inhibitors of interleukin-2 using fragment assembly. J. Med. Chem. (in the press). References 56–59 (and 62 below) detail an interdisciplinary approach, integrating fragment-based discovery, medicinal chemistry, and structural biology, to discovering inhibitors of the IL-2/IL-2R interaction.
- Hajduk, P. J. et al. High-throughput nuclear magnetic resonance-based screening. J. Med. Chem. 42, 2315–2317 (1999). · DOI · Paper page
Cited by
Items 101–200 of 1,003
Systematic Analysis of Helical Protein Interfaces Reveals Targets for Synthetic Inhibitors
Jochim, A. L., & Arora, P. S. (2010) · ACS Chemical Biology · doi:10.1021/cb1001747 · Cited by 191
“We propose that receptors with binding clefts are candidates for high-throughput screening efforts with small molecule libraries currently available to chemical biologists.(1,33) It is expected that several of these targets would not be of interest for inhibitor design owing to their biological function and other crit…”
BackgroundMolecular glues for protein-protein interactions: Progressing toward a new dream
Konstantinidou, M., & Arkin, M. R. (2024) · Cell Chemical Biology · doi:10.1016/j.chembiol.2024.04.002 · Cited by 187
Self-citationArkin, M. R., & Whitty, A. (2009) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2009.05.125 · Cited by 190
Self-citationTargeting G protein-coupled receptor signalling by blocking G proteins
Campbell, A. P., & Smrcka, A. V. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.135 · Cited by 188
Dragulescu-Andrasi, A., Chan, C. T., De, A., Massoud, T. F., & Gambhir, S. S. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1100923108 · Cited by 186
“P interactions (PPIs) are a prerequisite to most cellular processes, and their pharmacologic control offers promising avenues for therapeutic intervention in a variety of diseases (1).”
BackgroundTargeting protein–protein interactions: Lessons from p53/MDM2
Murray, J. K., & Gellman, S. H. (2007) · Peptide Science · doi:10.1002/bip.20741 · Cited by 186
Blurring the Role of Oligonucleotides: Spherical Nucleic Acids as a Drug Delivery Vehicle
Tan, X., Lu, X., Jia, F., Liu, X., Sun, Y., Logan, J. K., & Zhang, K. (2016) · Journal of the American Chemical Society · doi:10.1021/jacs.6b07554 · Cited by 184
Follis, A. V., Hammoudeh, D. I., Wang, H., Prochownik, E. V., & Metallo, S. J. (2008) · Chemistry & Biology · doi:10.1016/j.chembiol.2008.09.011 · Cited by 183
FOXM1 (Forkhead box M1) in Tumorigenesis
(2013) · Advances in Cancer Research · doi:10.1016/b978-0-12-407190-2.00016-2 · Cited by 184
Trosset, J., Dalvit, C., Knapp, S., Fasolini, M., Veronesi, M., Mantegani, S., Gianellini, L. M., Catana, C., Sundström, M., Stouten, P. F. W., et al. (2006) · Proteins: Structure, Function, and Bioinformatics · doi:10.1002/prot.20955 · Cited by 181
“Wells and coworkers showed, in fact, that most of the protein–protein-binding enthalpy is due to interactions with a small number of so-called “hot spots,” wellcharacterized patches on the surface of the proteins.(3,4) Engineered miniproteins with a small number of relevant residues, which are essential for binding, h…”
BackgroundWehbi, V. L., & Taskén, K. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00222 · Cited by 181
Inhibiting HIV-1 integrase by shifting its oligomerization equilibrium
Hayouka, Z., Rosenbluh, J., Levin, A., Loya, S., Lebendiker, M., Veprintsev, D., Kotler, M., Hizi, A., Loyter, A., & Friedler, A. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0700781104 · Cited by 181
Soares, P., Gadd, M. S., Frost, J., Galdeano, C., Ellis, L., Epemolu, O., Rocha, S., Read, K. D., & Ciulli, A. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00675 · Cited by 165
Macrocycles as protein–protein interaction inhibitors
Dougherty, P. G., Qian, Z., & Pei, D. (2017) · Biochemical Journal · doi:10.1042/bcj20160619 · Cited by 176
Hot spots in protein–protein interfaces: Towards drug discovery
Cukuroglu, E., Engin, H. B., Gursoy, A., & Keskin, O. (2014) · Progress in Biophysics and Molecular Biology · doi:10.1016/j.pbiomolbio.2014.06.003 · Cited by 177
“proteineprotein interfaces (Arkin and Wells, 2004).”
BackgroundProtein–protein interactions and cancer: small molecules going in for the kill
Arkin, M. (2005) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2005.03.001 · Cited by 175
Self-citationMechanisms of Protein Kinase A Anchoring
(2010) · International Review of Cell and Molecular Biology · doi:10.1016/s1937-6448(10)83005-9 · Cited by 175
Expanding the Number of ‘Druggable’ Targets: Non‐Enzymes and Protein–Protein Interactions
Makley, L. N., & Gestwicki, J. E. (2013) · Chemical Biology & Drug Design · doi:10.1111/cbdd.12066 · Cited by 176
“involved and the advantages of using allostery to disrupt these interfaces (21,22).”
BackgroundSadowsky, J. D., Fairlie, W. D., Hadley, E. B., Lee, H.-S., Umezawa, N., Nikolovska-Coleska, Z., Wang, S., Huang, D. C. S., Tomita, Y., & Gellman, S. H. (2007) · Journal of the American Chemical Society · doi:10.1021/ja0662523 · Cited by 174
Universal Screening Methods and Applications of ThermoFluor®
Cummings, M. D., Farnum, M. A., & Nelen, M. I. (2006) · SLAS Discovery · doi:10.1177/1087057106292746 · Cited by 175
Sadowsky, J. D., Schmitt, M. A., Lee, H.-S., Umezawa, N., Wang, S., Tomita, Y., & Gellman, S. H. (2005) · Journal of the American Chemical Society · doi:10.1021/ja053678t · Cited by 173
p53 Activation by Small Molecules: Application in Oncology
Vassilev, L. T. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm058174k · Cited by 174
Nandy, J. P., Prakesch, M., Khadem, S., Reddy, P. T., Sharma, U., & Arya, P. (2009) · Chemical Reviews · doi:10.1021/cr800188v · Cited by 171
Exploring Residue Component Contributions to Dynamical Network Models of Allostery
VanWart, A. T., Eargle, J., Luthey-Schulten, Z., & Amaro, R. E. (2012) · Journal of Chemical Theory and Computation · doi:10.1021/ct300377a · Cited by 171
“Experimental constructs to explore allostery have included x-ray crystallography with site-directed mutagenesis, 1 H-15 N heteronuclear single quantum correlation (HSQC) NMR, kinetic assays with site directed mutagenesis, inhibition assays, and others 16 .”
MethodBetween a rock and a hard place?
Whitty, A., & Kumaravel, G. (2006) · Nature Chemical Biology · doi:10.1038/nchembio0306-112 · Cited by 162
Emerging classes of protein–protein interaction inhibitors and new tools for their development
Pagliaro, L., Felding, J., Audouze, K., Nielsen, S. J., Terry, R. B., Krog-Jensen, C., & Butcher, S. (2004) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2004.06.006 · Cited by 168
“A recent review presents fragment-based discovery in the context of other approaches, and concludes that, while SMPPIIs remain challenging, real progress is being made [52].”
BackgroundA common allosteric site and mechanism in caspases
Scheer, J. M., Romanowski, M. J., & Wells, J. A. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0602571103 · Cited by 167
Self-citationTackling Drought Stress: RECEPTOR-LIKE KINASES Present New Approaches
Marshall, A., Aalen, R. B., Audenaert, D., Beeckman, T., Broadley, M. R., Butenko, M. A., Caño-Delgado, A. I., de Vries, S., Dresselhaus, T., Felix, G., et al. (2012) · The Plant Cell · doi:10.1105/tpc.112.096677 · Cited by 169
“Establishment of such screening systems will depend on physiological, biochemical, and biophysical knowledge of the respective target interactions (Arkin and Wells, 2004).”
BackgroundComputational design of peptide ligands
Vanhee, P., van der Sloot, A. M., Verschueren, E., Serrano, L., Rousseau, F., & Schymkowitz, J. (2011) · Trends in Biotechnology · doi:10.1016/j.tibtech.2011.01.004 · Cited by 166
Structure-Based Design of Novel Inhibitors of the MDM2–p53 Interaction
Rew, Y., Sun, D., Gonzalez-Lopez De Turiso, F., Bartberger, M. D., Beck, H. P., Canon, J., Chen, A., Chow, D., Deignan, J., Fox, B. M., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm300354j · Cited by 165
Protein–protein docking tested in blind predictions: the CAPRI experiment
Janin, J. (2010) · Molecular BioSystems · doi:10.1039/c005060c · Cited by 167
Design and Applications of Bifunctional Small Molecules: Why Two Heads Are Better Than One
Corson, T. W., Aberle, N., & Crews, C. M. (2008) · ACS Chemical Biology · doi:10.1021/cb8001792 · Cited by 165
“Using structure-based design, and known ligands for SAP (D-proline) and cholera toxin (m-nitrophenyl-α-D-galactopyranoside, MNPG), these authors produced a reagent (3) that bound SAP and cholera toxin simultaneously.”
Suzuki, T., Ota, Y., Ri, M., Bando, M., Gotoh, A., Itoh, Y., Tsumoto, H., Tatum, P. R., Mizukami, T., Nakagawa, H., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm300837y · Cited by 165
State-of-the-art strategies for targeting protein–protein interactions by small-molecule inhibitors
Sheng, C., Dong, G., Miao, Z., Zhang, W., & Wang, W. (2015) · Chemical Society Reviews · doi:10.1039/c5cs00252d · Cited by 165
Interfacial inhibition of macromolecular interactions: nature's paradigm for drug discovery
Pommier, Y., & Cherfils, J. (2005) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2005.01.008 · Cited by 165
Search strategies and evaluation in protein–protein docking: principles, advances and challenges
Huang, S.-Y. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2014.02.005 · Cited by 165
NMR-based analysis of protein–ligand interactions
Cala, O., Guillière, F., & Krimm, I. (2014) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-013-6931-0 · Cited by 165
Targeting protein–protein interactions by rational design: mimicry of protein surfaces
Fletcher, S., & Hamilton, A. D. (2006) · Journal of The Royal Society Interface · doi:10.1098/rsif.2006.0115 · Cited by 164
“Nevertheless, despite such challenges, there has been a number of advances in this area of research (Arkin & Wells 2004; Pagliaro et al. 2004; Zhao & Chmielewski 2005; Yin & Hamilton 2005; Fletcher & Hamilton 2005).”
BackgroundSmall molecule compounds targeting miRNAs for cancer therapy
Monroig, P. D. C., Chen, L., Zhang, S., & Calin, G. A. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.09.002 · Cited by 162
“Small molecules have been thoroughly used with clinical applications for numerous diseases but also specifically for cancer [34,35].”
BackgroundVisualization and targeted disruption of protein interactions in living cells
Herce, H. D., Deng, W., Helma, J., Leonhardt, H., & Cardoso, M. C. (2013) · Nature Communications · doi:10.1038/ncomms3660 · Cited by 162
Lee, E. F., Sadowsky, J. D., Smith, B. J., Czabotar, P. E., Peterson‐Kaufman, K. J., Colman, P. M., Gellman, S. H., & Fairlie, W. D. (2009) · Angewandte Chemie International Edition · doi:10.1002/anie.200805761 · Cited by 160
A polymer nanoparticle with engineered affinity for a vascular endothelial growth factor (VEGF165)
Koide, H., Yoshimatsu, K., Hoshino, Y., Lee, S.-H., Okajima, A., Ariizumi, S., Narita, Y., Yonamine, Y., Weisman, A. C., Nishimura, Y., et al. (2017) · Nature Chemistry · doi:10.1038/nchem.2749 · Cited by 158
Pelz, N. F., Bian, Z., Zhao, B., Shaw, S., Tarr, J. C., Belmar, J., Gregg, C., Camper, D. V., Goodwin, C. M., Arnold, A. L., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01660 · Cited by 150
Hierarchical virtual screening approaches in small molecule drug discovery
Kumar, A., & Zhang, K. Y. J. (2015) · Methods · doi:10.1016/j.ymeth.2014.07.007 · Cited by 157
α/β-Peptide foldamers: state of the art
Pilsl, L. K. A., & Reiser, O. (2011) · Amino Acids · doi:10.1007/s00726-011-0894-2 · Cited by 156
Targeting protein–protein interactions for cancer therapy
Fry, D. C., & Vassilev, L. T. (2005) · Journal of Molecular Medicine · doi:10.1007/s00109-005-0705-x · Cited by 160
The Discovery of LOX-1, its Ligands and Clinical Significance
Yoshimoto, R., Fujita, Y., Kakino, A., Iwamoto, S., Takaya, T., & Sawamura, T. (2011) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-011-6324-6 · Cited by 154
Oncogenic Partnerships: EWS-FLI1 Protein Interactions Initiate Key Pathways of Ewing's Sarcoma
Erkizan, H. V., Uversky, V. N., & Toretsky, J. A. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2261 · Cited by 160
Small-molecule inhibitors of the Myc oncoprotein
Fletcher, S., & Prochownik, E. V. (2015) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2014.03.005 · Cited by 152
“For these reasons, PPIs have long been considered to be “undruggable” [119,121, 122].”
Buckley, D. L., & Crews, C. M. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201307761 · Cited by 153
Oh, S., & Park, S. B. (2011) · Chemical Communications · doi:10.1039/c1cc14042f · Cited by 155
Jubb, H. C., Pandurangan, A. P., Turner, M. A., Ochoa-Montaño, B., Blundell, T. L., & Ascher, D. B. (2017) · Progress in Biophysics and Molecular Biology · doi:10.1016/j.pbiomolbio.2016.10.002 · Cited by 154
“While orthosteric inhibition has been the focus of much early attention and successes in the field (Arkin and Wells, 2004; Sigurdardottir et al., 2015), and has paved the way for further exploration of PPI modulators with respect to driving thinking in computational, fragment-based, and natural…”
BackgroundTargeting MDM2-p53 Interaction for Cancer Therapy: Are We There Yet?
Nag, S., Zhang, X., Srivenugopal, K. S., Wang, M.-H., Wang, W., & Zhang, R. (2014) · Current Medicinal Chemistry · doi:10.2174/09298673113206660325 · Cited by 149
“Most new chemical entities developed as MDM2 inhibitors are based on this principle [222].”
BackgroundSequence‐Based Design of α/β‐Peptide Foldamers That Mimic BH3 Domains
Horne, W. S., Boersma, M. D., Windsor, M. A., & Gellman, S. H. (2008) · Angewandte Chemie International Edition · doi:10.1002/anie.200705315 · Cited by 151
Inhibitor of MYC identified in a Kröhnke pyridine library
Hart, J. R., Garner, A. L., Yu, J., Ito, Y., Sun, M., Ueno, L., Rhee, J.-K., Baksh, M. M., Stefan, E., Hartl, M., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1319488111 · Cited by 147
KFC Server: interactive forecasting of protein interaction hot spots
Darnell, S. J., LeGault, L., & Mitchell, J. C. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkn346 · Cited by 152
“In addition to mutation studies, hot spots are also receiving attention as potential binding motifs for small molecule inhibitors of protein interactions ( 7 ,8).”
BackgroundFuzziness in Protein Interactions—A Historical Perspective
Fuxreiter, M. (2018) · Journal of Molecular Biology · doi:10.1016/j.jmb.2018.02.015 · Cited by 143
“Indeed, small molecules inhibiting proteinprotein interactions usually target dynamic interfaces [103].”
BackgroundMolecular Glue Discovery: Current and Future Approaches
Dewey, J. A., Delalande, C., Azizi, S.-A., Lu, V., Antonopoulos, D., & Babnigg, G. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00449 · Cited by 138
Bojadzic, D., Alcazar, O., Chen, J., Chuang, S.-T., Capcha, J. M. C., Shehadeh, L. A., & Buchwald, P. (2021) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.1c00070 · Cited by 154
Novel approaches to inhibiting HIV-1 replication
Adamson, C. S., & Freed, E. O. (2010) · Antiviral Research · doi:10.1016/j.antiviral.2009.09.009 · Cited by 144
“The fact that assembly inhibitors will target interacting surfaces that may be relatively flat and cover large areas, and are therefore problematic for drug discovery, represents a significant future challenge for the development of this class of antiretrovirals (Arkin and Wells, 2004).”
BackgroundTrapping Moving Targets with Small Molecules
Lee, G. M., & Craik, C. S. (2009) · Science · doi:10.1126/science.1169378 · Cited by 145
Discovery of Chromone‐Based Inhibitors of the Transcription Factor STAT5
Müller, J., Sperl, B., Reindl, W., Kiessling, A., & Berg, T. (2008) · ChemBioChem · doi:10.1002/cbic.200700701 · Cited by 145
Hodge, J. W., Ardiani, A., Farsaci, B., Kwilas, A. R., & Gameiro, S. R. (2012) · Seminars in Oncology · doi:10.1053/j.seminoncol.2012.02.006 · Cited by 155
Shaginian, A., Whitby, L. R., Hong, S., Hwang, I., Farooqi, B., Searcey, M., Chen, J., Vogt, P. K., & Boger, D. L. (2009) · Journal of the American Chemical Society · doi:10.1021/ja810025g · Cited by 143
Hot spot-based design of small-molecule inhibitors for protein–protein interactions
Guo, W., Wisniewski, J. A., & Ji, H. (2014) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2014.03.095 · Cited by 142
Small Targeted Cytotoxics: Current State and Promises from DNA‐Encoded Chemical Libraries
Krall, N., Scheuermann, J., & Neri, D. (2013) · Angewandte Chemie International Edition · doi:10.1002/anie.201204631 · Cited by 163
Exploring New Chemical Space by Stereocontrolled Diversity-Oriented Synthesis
Arya, P., Joseph, R., Gan, Z., & Rakić, B. (2005) · Chemistry & Biology · doi:10.1016/j.chembiol.2005.01.011 · Cited by 142
Oligobenzamide proteomimetic inhibitors of the p53–hDM2 protein–protein interaction
Plante, J. P., Burnley, T., Malkova, B., Webb, M. E., Warriner, S. L., Edwards, T. A., & Wilson, A. J. (2009) · Chemical Communications · doi:10.1039/b908207g · Cited by 141
Natural products and Pharma 2011: Strategic changes spur new opportunities
Carter, G. T. (2011) · Natural Product Reports · doi:10.1039/c1np00033k · Cited by 142
Hot-spot mimicry of a cytokine receptor by a small molecule
Thanos, C. D., DeLano, W. L., & Wells, J. A. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0607058103 · Cited by 141
Self-citationMimicking nature with synthetic macromolecules capable of recognition
Mahon, C. S., & Fulton, D. A. (2014) · Nature Chemistry · doi:10.1038/nchem.1994 · Cited by 142
Real-Time Biomolecular Binding Detection Using a Sensitive Photonic Crystal Biosensor
Guo, Y., Ye, J. Y., Divin, C. J., Huang, B., Thomas, T. P., Baker, J. R., & Norris, T. B. (2010) · Analytical Chemistry · doi:10.1021/ac100576y · Cited by 139
Biosensor-based small molecule fragment screening with biolayer interferometry
Wartchow, C. A., Podlaski, F., Li, S., Rowan, K., Zhang, X., Mark, D., & Huang, K. (2011) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-011-9439-8 · Cited by 138
Organic synthesis toward small-molecule probes and drugs
Schreiber, S. L. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1103205108 · Cited by 137
“More recent studies showing that small molecules can be discovered that (i) modulate the cellular functions of extracellular growth factors (15) and intracellular transcription factors (16), proteins lacking enzymatic activities, and (ii) disrupt protein/protein interactions (17, 18), activate or inactivate autophagy…”
BackgroundSmall molecules that inhibit TNF signalling by stabilising an asymmetric form of the trimer
O’Connell, J. P., Porter, J. R., Kroeplien, B., Norman, T., Rapecki, S., Davis, R., McMillan, D., Arakaki, T. L., Burgin, A. B., Fox, D., III, et al. (2019) · Nature Communications · doi:10.1038/s41467-019-13616-1 · Cited by 147
A three-stage biophysical screening cascade for fragment-based drug discovery
Mashalidis, E. H., Sledz, P., Lang, S., & Abell, C. (2013) · Nature Protocols · doi:10.1038/nprot.2013.130 · Cited by 144
Ivarsson, Y., Arnold, R., McLaughlin, M., Nim, S., Joshi, R., Ray, D., Liu, B., Teyra, J., Pawson, T., Moffat, J., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1312296111 · Cited by 135
“These interactions are integral to cellular function and mediate signaling pathways that are often misregulated in cancer (2) and may be hijacked by viral proteins (3).”
BackgroundRoman, D. L., Talbot, J. N., Roof, R. A., Sunahara, R. K., Traynor, J. R., & Neubig, R. R. (2006) · Molecular Pharmacology · doi:10.1124/mol.106.028670 · Cited by 156
“Inhibition of signaling networks through disruption of protein-protein interactions presents unique new targets for the development of chemical tools and for possible therapeutic drug discovery (Arkin and Wells, 2004; Pagliaro et al., 2004).”
BackgroundValidation of the Hsp70–Bag3 Protein–Protein Interaction as a Potential Therapeutic Target in Cancer
Li, X., Colvin, T. A., Rauch, J. N., Acosta‐Alvear, D., Kampmann, M., Dunyak, B. M., Hann, B. C., Aftab, B. T., Murnane, M., Cho, M. Y., et al. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0650 · Cited by 138
“In the ongoing search for new cancer targets, a number of promising PPIs have emerged (17, 18).”
Ciulli, A., Williams, G., Smith, A. G., Blundell, T. L., & Abell, C. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm060490r · Cited by 134
Buchwald, P. (2010) · IUBMB Life · doi:10.1002/iub.383 · Cited by 133
“2, navitoclax (10, ABT-263) is a modification of the original lead ABT-737 (9) specifically designed to improve oral bioavailability (29).”
BackgroundVirstatin inhibits dimerization of the transcriptional activator ToxT
Shakhnovich, E. A., Hung, D. T., Pierson, E. R., Lee, K., & Mekalanos, J. J. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0611643104 · Cited by 133
Protein surface recognition and proteomimetics: mimics of protein surface structure and function
Fletcher, S., & Hamilton, A. D. (2005) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2005.10.006 · Cited by 135
McKee, C. J., Kessl, J. J., Shkriabai, N., Dar, M. J., Engelman, A., & Kvaratskhelia, M. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m805843200 · Cited by 129
Ward, A., Khanna, K. K., & Wiegmans, A. P. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2014.10.006 · Cited by 139
“Small molecule inhibitors are a class of low molecular weight, organic compounds that bind to the active site of a target protein to interfere with enzyme activity or protein–protein interactions [56,57].”
BackgroundIntegrase, LEDGF/p75 and HIV replication
Poeschla, E. M. (2008) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-008-7540-5 · Cited by 165
Betzi, S., Restouin, A., Opi, S., Arold, S. T., Parrot, I., Guerlesquin, F., Morelli, X., & Collette, Y. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0707130104 · Cited by 125
Protein–protein binding affinity prediction from amino acid sequence
Yugandhar, K., & Gromiha, M. M. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btu580 · Cited by 124
“…the importance of charged residues in binding sites and their role as anchor residues in the binding pockets of protein–protein complexes mainly by forming inter molecular hydrogen bonds apart from salt bridges (Arkin and Wells, 2004; Rajamani et al ., 2004; Sheinerman et al ., 2000; Stites, 1997).”
BackgroundWu, G., Qiu, X., Zhou, L., Zhu, J., Chamberlin, R., Lau, J. Y. N., Chen, P., & Lee, W. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1915 · Cited by 124
“Notably, for human cells, the GI50s of INH1 are at a similar micromolar level to other known protein-protein interaction inhibitors such as those for androgen receptor, interleukin-2, and BCL-2 (43, 44).”
Using a Fragment‐Based Approach To Target Protein–Protein Interactions
Scott, D. E., Ehebauer, M. T., Pukala, T., Marsh, M., Blundell, T. L., Venkitaraman, A. R., Abell, C., & Hyvönen, M. (2013) · ChemBioChem · doi:10.1002/cbic.201200521 · Cited by 125
Protein–protein interactions as targets for small-molecule therapeutics in cancer
White, A. W., Westwell, A. D., & Brahemi, G. (2008) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399408000641 · Cited by 122
Engineering and Identifying Supercharged Proteins for Macromolecule Delivery into Mammalian Cells
Thompson, D. B., Cronican, J. J., & Liu, D. R. (2012) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/b978-0-12-396962-0.00012-4 · Cited by 124
“Moreover, the strength of macromolecule-target binding can be sufficient to interfere with native protein–protein or protein–nucleic acid interfaces that have traditionally been difficult to address using small molecules (Arkin and Wells, 2004).”
Relationship between Hot Spot Residues and Ligand Binding Hot Spots in Protein–Protein Interfaces
Zerbe, B. S., Hall, D. R., Vajda, S., Whitty, A., & Kozakov, D. (2012) · Journal of Chemical Information and Modeling · doi:10.1021/ci300175u · Cited by 121
Why Some Targets Benefit from beyond Rule of Five Drugs
Egbert, M., Whitty, A., Keserű, G. M., & Vajda, S. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01732 · Cited by 118
Qi, W., Shakalya, K., Stejskal, A., Goldman, A. J., Beeck, S., Cooke, L. S., & Mahadevan, D. (2008) · Oncogene · doi:10.1038/onc.2008.54 · Cited by 120
“dtd"[ ]> Introduction Nucleophosmin (NPM), also known as B23, NO38 or numatrin (”
Identification of hot-spot residues in protein-protein interactions by computational docking
Grosdidier, S., & Fernández-Recio, J. (2008) · BMC Bioinformatics · doi:10.1186/1471-2105-9-447 · Cited by 120
Kong, X., Chen, L., Jiao, L., Jiang, X., Lian, F., Lu, J., Zhu, K., Du, D., Liu, J., Ding, H., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm501230c · Cited by 121
Anatomy of β-Strands at Protein–Protein Interfaces
Watkins, A. M., & Arora, P. S. (2014) · ACS Chemical Biology · doi:10.1021/cb500241y · Cited by 116
Interaction Entropy for Computational Alanine Scanning
Yan, Y., Yang, M., Ji, C., & Zhang, J. Z. H. (2017) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.6b00734 · Cited by 120
Wang, T., Wu, X., Guo, C., Zhang, K., Xu, J., Li, Z., & Jiang, S. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00990 · Cited by 124
Metadata
- Authors
- Arkin, M. R., & Wells, J. A.
- Affiliations
- Sunesis (United States) (US)
- Venue
- Nature Reviews Drug Discovery
- Published
- 2004-04
- Volume
- 3
- Issue
- 4
- Pages
- 301-317
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2167398093
- Cited by
- 1,705
- References
- 178
- Citations by year
- 2026: 52 · 2025: 48 · 2024: 39 · 2023: 51 · 2022: 46 · 2021: 61 · 2020: 54 · 2019: 71 · 2018: 73 · 2017: 61 · 2016: 99 · 2015: 101 · 2014: 126 · 2013: 110 · 2012: 110
- FWCI
- 5.99
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Keywords
- protein-protein interaction, small molecule inhibitors, drug discovery, binding pocket, therapeutic target, inhibitor characterization
- MeSH terms
- Animals, Binding Sites, Enzyme Inhibitors, Humans, Protein Binding, Proteins, Receptors, Cell Surface, Drug Design, Computational Biology
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.